Navigation Links
LeMaitre Vascular Reports Q3 2007 Revenue of $10.1 Million, a 19% Increase
Date:11/5/2007

undisclosed sum. The Company believes that Serom's hospital-level sales of LeMaitre Vascular products were approximately 1.9 million euros in 2006.

George W. LeMaitre, Chairman and CEO said, "This was another solid quarter for LeMaitre Vascular. We continued to post strong top-line growth while keeping operating expenses under control. Additionally, we completed a meaningful acquisition and furthered our European 'go-direct' strategy. With regard to Vascular Architects, we are happy to combine a suite of unique vascular products with our dedicated vascular surgery sales force. Going direct in Italy will allow us to control our sales channel in the fifth largest vascular market in the world."

The operating loss for Q3 2007 was $1,541,000, compared to operating income of $342,000 for Q3 2006. The Q3 2007 operating loss was due to a $1,054,000 charge related to distributor buyouts, increased sales force and R&D expenditures, and the costs associated with being a public company.

The Company reported a net loss of $1,354,000, or $0.09 per basic and diluted share for Q3 2007, compared to net income of $221,000, or $0.01 per basic and diluted share, for Q3 2006. The Q3 2007 net loss benefited from interest income of $359,000, as well as a $221,000 foreign exchange gain.

Sales and marketing expenses for Q3 2007 increased 30% to $4,583,000 from $3,525,000 for Q3 2006. The Company ended Q3 2007 with 58 sales representatives, compared to 36 at the end of Q3 2006.

For Q3 2007, general and administrative expenses increased by 52% over Q3 2006, from $1,536,000 to $2,341,000, primarily due to the higher costs associated with being a publicly traded company. Q3 2006 was the Company's last full quarter as a private company.

R & D expenses increased 42% to $1,144,000 for Q3 2007, compared to $805,000 for Q3 2006. The increase was driven largely by the hiring of additional product development engineers and related product development expenses.

'/>"/>
SOURCE LeMaitre Vascular, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. LeMaitre Vascular to Start Italian Sales Force
2. LeMaitre Vascular to Participate at CIBC 18th Annual Healthcare Conference
3. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
4. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
5. Pot bellies linked to early signs of cardiovascular disease
6. Air pollution linked to cardiovascular risk indices in healthy young adults
7. Environmental stress probed in cardiovascular disease, diabetes
8. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
9. American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC)
10. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
11. GrantAdler Shipping Novel Implantable Vascular Access Port
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Colo. (May 21, 2013) Research into genetic features ... University of Colorado School of Medicine may lead to ... a paper published online by JAMA . , ... predict survival in some cases of pulmonary fibrosis, a ... years. As a result of the study, researchers may ...
(Date:5/21/2013)... May 21, 2013 The Las Vegas personal ... to announce that Crawford Gates, a senior at Coronado High ... college scholarship essay contest . As the winner of the ... essay contest started on Dec. 1, 2012 and ran through ... to submit a three-page minimum essay on “The Role of ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 While ... is synonymous with comprehensive travel guides. Brunswick Plantation & ... golf packages that include access to 27 holes of ... golf courses in North Carolina, knowing the Top ... and Lodges takes away the overwhelming task of selecting ...
(Date:5/21/2013)... Aggressive treatment for prostate cancer may not be ... conditions, a new study finds. Treatments for ... seed implants, can cause serious side effects, such ... explained researchers from the University of California, Los ... patients with slower growing forms of prostate cancer ...
(Date:5/21/2013)... as 35 percent of Mexican young adults may have ... Illinois scientist who conducted a study at the Universidad ... inherited genetic risk factors from both parents were already ... waist than those who hadn,t. They also had slightly ... of I professor of food science and human nutrition. ...
Breaking Medicine News(10 mins):Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest 2Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2Health News:Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary 2Health News:Genetic risk for obesity found in many Mexican young adults 2
... could lead to new birth control for men , WEDNESDAY, ... of proteins called PLA2s play a vital role in sperm ... , The findings could improve understanding of male infertility and ... for infertility. , In one study, Japanese researchers found that ...
... ... share the leading position in the European Union’s “Novel Foods” category , ... Provo, UT (Vocus) April 28, 2010 -- ... Commission on Food Safety. Now, not only do noni juice and noni leaf have Novel ...
... ... that more than 100 baby boys die from circumcision complications each year, including from ... deaths are avoidable. , ... (PRWEB) April 28, 2010 -- The International Coalition for Genital Integrity (ICGI) acknowledges ...
... ... elegant celebration of the unique bond between adults and their moms - has been released publicly ... ... A Poem for Mothers - I Honor You " by bestselling author Brian Vaszily has been ...
... ... Brooklyn Bridge Park playground is closed for renovation less than a month after opening. ... New York (PRWEB) April 28, ... down this week. Less than a month after it opened, the much-anticipated playground was declared ...
... ... Develop a 100 Percent Lead Free Bubbler Retrofit Kit , ... Los Angeles, CA (Vocus) April 28, 2010 -- Acorn ... and a division of Acorn Engineering Company, announces a 100 percent lead-free bubbler retrofit kit ...
Cached Medicine News:Health News:Third European Novel Food Approval Received by Tahitian Noni International 2Health News:Children's Rights Group Agrees with New Study: Infant Circumcision Causes 100 Deaths Each Year in US 2Health News:Inspirational Short Video for Adults Who Celebrate Their Mothers Called "A Poem for Mothers" Released on YouTube 2Health News:Inspirational Short Video for Adults Who Celebrate Their Mothers Called "A Poem for Mothers" Released on YouTube 3Health News:New York Personal Injury Lawyer, David Perecman, says New Playground is No Place for Kids 2Health News:New York Personal Injury Lawyer, David Perecman, says New Playground is No Place for Kids 3Health News:The Acorn Aqua's Lead Free Bubbler 2
(Date:5/21/2013)... , May 21, 2013  Janssen R&D ... results from the global Phase 3 PROMISE study ... simeprevir (TMC435) led to sustained virologic response 12 ... 79 percent of treatment-experienced genotype 1 chronic hepatitis ... all stages of liver fibrosis, when administered once ...
(Date:5/21/2013)... 21, 2013 Abaxis, Inc. (NasdaqGS: ABAX), a ... today that Martin Mulroy , chief ... Dental & Veterinary Conference on Wednesday, May 29, 2013 ... at Le Parker Meridien Hotel in New ... Abaxis develops, manufactures, markets and sells portable blood ...
(Date:5/21/2013)... -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: ... cell based therapies for various personal applications, announced that ... CEO, will be presenting at the Marcum MicroCap Conference.   ... Thursday, May 30, 2013 at the Grand Hyatt Hotel, ... City.  Mr. Weinreb,s presentation will take place at 2:30 ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
... Reported Consistent Pain-Free,Results From Attack to Attack, BOSTON, ... from,migraines frequently cite inconsistent effectiveness as a reason,for ... more,than 1,100 patients show that the investigational migraine ... two and,four hours, as well as a sustained ...
... 2, 2007 - Pluristem Life Systems,Inc. (OTCBB:PLRS), a ... for a variety of indications,announced today that it ... Meeting of the International Society for Cellular,Therapy (ICST), ... and Chairman, Mr. Zami Aberman commented, "We are,receiving ...
Cached Medicine Technology:Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across,Multiple Migraine Attacks 2Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across,Multiple Migraine Attacks 3Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across,Multiple Migraine Attacks 4Pluristem to Present Two Scientific Posters at the International,Society for Cellular Therapy 2Pluristem to Present Two Scientific Posters at the International,Society for Cellular Therapy 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: